By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acceleron Pharma 

128 Sidney Street

Cambridge  Massachusetts    U.S.A.
Phone: 617-649-9200 Fax: 617-649-9988





Company News
Acceleron Pharma Announces Pricing Of Public Offering Of Common Stock 9/21/2017 6:50:09 AM
Acceleron Pharma Announces Proposed Public Offering Of Common Stock 9/20/2017 6:45:21 AM
Acceleron Pharma Showcases Vision And Strategy At 2017 R&D Day 9/19/2017 11:02:16 AM
Acceleron Pharma To Develop Sotatercept In Pulmonary Arterial Hypertension 9/19/2017 6:37:19 AM
Acceleron Pharma To Host Research And Development Day On September 19, 2017 9/12/2017 10:52:44 AM
Acceleron Pharma Announces Publication Of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results In The Lancet Oncology 9/5/2017 8:34:03 AM
Acceleron Pharma Reports Second Quarter 2017 Operational And Financial Results 8/4/2017 7:50:15 AM
Acceleron Pharma Announces First Patient Treated In Phase II Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease 8/1/2017 7:37:23 AM
Acceleron Pharma To Webcast Second Quarter 2017 Financial Results On August 3, 2017 7/27/2017 6:18:53 AM
Acceleron Pharma Provides Updated Results From Ongoing Phase II Study Of Luspatercept In Myelodysplastic Syndromes At The 22nd Congress Of The European Hematology Association 6/23/2017 6:58:19 AM